v-ATPase V0 subunit d2–deficient mice exhibit impaired osteoclast fusion and increased bone formation

Seoung-Hoon Lee,Jaerang Rho,Daewon Jeong,Jai-Yoon Sul,Taesoo Kim,Nacksung Kim,Ju-Seob Kang,Takeshi Miyamoto,Toshio Suda,Sun-Kyeong Lee,Robert J Pignolo,Boguslawa Koczon-Jaremko,Joseph Lorenzo,Yongwon Choi
DOI: https://doi.org/10.1038/nm1514
IF: 82.9
2006-11-26
Nature Medicine
Abstract:Matrix-producing osteoblasts and bone-resorbing osteoclasts maintain bone homeostasis. Osteoclasts are multinucleated, giant cells of hematopoietic origin formed by the fusion of mononuclear pre-osteoclasts derived from myeloid cells1,2. Fusion-mediated giant cell formation is critical for osteoclast maturation; without it, bone resorption is inefficient2,3. To understand how osteoclasts differ from other myeloid lineage cells, we previously compared global mRNA expression patterns in these cells and identified genes of unknown function predominantly expressed in osteoclasts, one of which is the d2 isoform of vacuolar (H+) ATPase (v-ATPase) V0 domain (Atp6v0d2)4,5,6,7. Here we show that inactivation of Atp6v0d2 in mice results in markedly increased bone mass due to defective osteoclasts and enhanced bone formation. Atp6v0d2 deficiency did not affect differentiation or the v-ATPase activity of osteoclasts. Rather, Atp6v0d2 was required for efficient pre-osteoclast fusion. Increased bone formation was probably due to osteoblast-extrinsic factors, as Atp6v02 was not expressed in osteoblasts and their differentiation ex vivo was not altered in the absence of Atp6v02. Our results identify Atp6v0d2 as a regulator of osteoclast fusion and bone formation, and provide genetic data showing that it is possible to simultaneously inhibit osteoclast maturation and stimulate bone formation by therapeutically targeting the function of a single gene.
biochemistry & molecular biology,cell biology,medicine, research & experimental
What problem does this paper attempt to address?